Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for caplacizumab (Cablivi) for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.